Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4816—Wall or shell material
  • A61K9/4825—Proteins, e.g. gelatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/4841—Filling excipients; Inactive ingredients
  • A61K9/4866—Organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
  • A61P25/36—Opioid-abuse

Definitions

• the present invention relates to the use of a combination of morphine and at least one opiate antagonist, in particular naloxone, to treat opiate dependency in humans.
• the invention further relates to the use of a combination of an opiate and at least one opiate antagonist to prevent non-oral opiate abuse among opiate addicts.
• Drug addiction continues to be a problem in our society. It is common knowledge that taking certain substances such as for example heroin leads to dependency. A distinction is made here between a physical dependency and mental drug dependency (drug addiction). Physical drug dependency occurs when there is an abrupt cessation or significant reduction in the quantity of the substance taken. There are withdrawal symptoms such as vomiting and cramps of the gastrointestinal tract. A distinction is made between this and actual drug addiction, mental dependency, which is regarded as a separate neurological disorder. Symptoms of drug addiction are a failure to control one's own use of the drug, self-endangerment and a compulsive desire to acquire the drug.
• opioid addiction within the scope of the present invention is meant in particular an opiate dependency (mental and behavioural disorders due to opioids; F11 of ICD-10).
• a heroin dependency or opiate dependency can be treated particularly well with the present method.
• Drug addiction is currently treated by switching the patient from a dangerous drug to a less dangerous substitute, or reducing the patient's dose under controlled conditions. However, for various reasons not every drug is accepted by patients. Methadone, heroin, buprenorphine and morphine are used as substitutes. Methadone is a synthetic opiate with the formula:
• Methadone has been used as a substitute since the 1960s, both in the optically active L-form and in the racemate form. Methadone is suitable for satisfactorily alleviating withdrawal symptoms, especially in heroin patients. It has a longer-lasting effect than heroin, can be taken orally without any appreciable loss of effect and does not produce a “kick” (i.e. the especially euphoric feeling which is triggered e.g. by heroin and leads to drug addiction). In order to prevent an improper intravenous administration, methadone is often given in the form of a syrup mixed with sugar or orange juice in addiction treatment programmes.
• methadone differs from one individual to another and its administration is therefore not simple. Methadone also produces a high level of dependency. Methadone withdrawal symptoms actually last longer than those of heroin. Methadone, like all opiates, leads to constipation, as it has a paralyzing effect on the gastrointestinal musculature. In addition, methadone seems to have significant side-effects.
• a dosage form with retarded morphine and retarded naloxone is known from WO 97/33566 A2.
• This dosage form contains a semipermeable wall which surrounds a two-layered core consisting of an opioid (outer layer) and—separate from it—an antagonist (inner layer).
• the physical separation of the opioid and the antagonist means it is easy for the drug addict to obtain the opioid through separation measures, for example by first scraping off the outer wall of the dosage form and then removing the outer shell from the exposed core.
• Controlled-release preparations based on retarded morphine and a retarded antagonist are known from WO 01/58447 A1. However, there is no indication that the antagonist is to have a low bioavailability.
• Pain-therapy preparations based on retarded morphine and non-retarded naloxone are known from WO 99/32119 A1 and DE 43 25 465 A1, without affecting the field of application of the present invention.
• Combination preparations consisting of particular opioid analgesics and naloxone are also known from the state of the art.
• the commercial product Talwin®Nx contains pentazocine and naloxone.
• the product Valoron®N contains tilidine and naloxone.
• the emphasis in the state of the art has been more on attempts to make it impossible to use the corresponding preparations as drugs.
• buprenorphine is suitable as a substitute for only some opiate addicts.
• a combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% when administered orally represents a suitable substitute for the treatment of drug addiction. At the same time non-oral abuse is reliably prevented.
• the present invention therefore relates to the use of a non-separable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% when administered orally for the preparation of a medicinal product to be administered only orally to treat drug addiction in humans, in particular for substitution therapy among drug addicts.
• the present invention also relates to the use of a non-separable combination of an opiate, preferably morphine, and at least one opiate antagonist with a bioavailability of less than 5% when administered orally to prepare a medicinal product to be administered only orally to prevent non-oral opiate abuse among opiate addicts.
• the substance combination according to the invention surprisingly represents an ideal substitute.
• its receptor profile and its physiological degradation pathway are particularly advantageous within the framework of a substitution therapy.
• the substance combinations according to the invention prevent their non-oral abuse.
• non-oral abuse is meant intravenous, pulmonary (through smoking), nasal, sublingual or rectal abuse.
• drug addict attempts to achieve the intoxicating effect by application paths not provided for by the manufacturer of a corresponding preparation.
• a preparation is melted or dissolved and injected intravenously or a preparation is burnt on aluminium foil and the smoke inhaled (pulmonary abuse; foil smoking).
• the selection according to the invention of antagonists having a low bioavailability when applied orally, i.e. a bioavailability of less than 5% when administered orally, and an agonist with a bioavailability that is adequate for physiological blood levels when administered orally, ensures that the combination preparation according to the invention leads to a good substitution result only if it is taken orally. If it is taken in other ways, for example by the intravenous, pulmonary, nasal or rectal route, where the first-pass metabolism through the liver and/or metabolism in the intestinal wall and the cleavage activity of the digestive enzymes are avoided, withdrawal symptoms occur directly, as the antagonist takes full effect.
• a particular advantage of the present invention is that the patient, i.e. the drug addict, cannot separate the morphine or more generally the opiate from the antagonist.
• Administration forms suitable for this purpose are for example those in which agonist and antagonist are present as a powder or granule mixture.
• Suitable powders can have grain sizes of 25 ⁇ m to 0.1 mm
• suitable granules can have grain sizes of 0.1 mm to 2 mm (in each case the maximum size of all the particles present in the mixture). Determination of the particle sizes can be carried out by separation methods, wherein sieve separation is particularly suitable. With this embodiment, because of the mixing and visual indistinguishability of the different particles, it is not possible for the drug addict to separate with certainty the individual particles of the mixture into agonists and antagonists.
• Administration forms in which agonist and antagonist are present embedded together in a matrix and for example compressed into a tablet are also suitable.
• the drug addict it is no longer possible for the drug addict to separate the active ingredients from the matrix.
• the result of dissolution in a solvent is that all the ingredients are equally dissolved and a separation with means available to the drug addict is no longer possible.
• a mechanical division of the matrix containing the active ingredients allow the agonist to be obtained separately from the antagonist.
• a non-separable administration form of agonists and antagonists is chosen which does not allow a separation of the mixture into agonists and antagonists by mechanical and/or visual separation methods, i.e. for example by visual inspection followed by manual separation of the different constituents of the mixture, or by dissolving the mixture and then evaporating and/or precipitating the individual constituents of the mixture.
• all known opiates can be used in combination with a corresponding antagonist countering the effect of the opiate.
• opiates include for example morphine, codeine, papaverine and thebaine. Morphine is particularly preferred.
• Morphine is used within the framework of the use according to the invention in the substitution therapy.
• Morphine is an opiate with the formula:
• Morphine also colloquially called morphia, is a very effective painkiller which can be extracted from the seeds of the opium poppy. Just like heroin, it is addictive, but it is less effective.
• morphine is administered in retarded or non-retarded form.
• a retarded form (or retard form) of a medicinal product is meant an administration form in which the release of the active ingredient is slowed down.
• the active ingredient can be released in the body in a controlled manner and thus prevent possibly dangerous concentration peaks of the active ingredient in the blood.
• the medicinal product is effective for longer in the patient. The active ingredient therefore needs to be taken less often.
• a retarded form of morphine is preferred. This can make it possible for the opiate to be taken only once or twice daily.
• the substitute needs to be taken less frequently. Because of the longer-lasting effect of the morphine, the drug addict's need to obtain a fresh supply of intoxicants as soon as possible is alleviated. In addition, the dangers of an overdose are alleviated by the retard form, as the active ingredient is passed into the blood in a controlled manner, avoiding concentration peaks.
• Retarded forms of opiates and in particular of morphine are sufficiently known to a person skilled in the art.
• every retarded form of morphine and more generally opiate can be used.
• a formulation is preferred in which the morphine is adsorbed on a polymer, for example a hydrophilic polymer, and embedded in a matrix, for example a hydrophobic matrix.
• the antagonist is preferably also located in the matrix, in order to ensure the non-separability according to the invention.
• the polymer is preferably a cellulose polymer and the matrix a wax. On contact with the gastric juice the polymer forms a gel through which the active ingredient can pass only with a delay.
• Another preferred retard formulation is characterized in that, in a liquid administration form, the morphine is suspended in an ethyl cellulose polymer and released only with a delay.
• Another common retard form is a tablet coated with a protective layer. The protective layer dissolves only slowly in the gastric juice and the release of the active ingredient is correspondingly delayed.
• the opiates can be administered in all the usual administration forms according to the present invention.
• Physiologically acceptable salts such as hydrochlorides, hydrates, sulphates, chlorates and quaternary salts are preferred.
• Particularly preferred morphine salts are morphine hydrochloride, morphine sulphate pentahydrate, morphine chlorate, morphine methobromide and other quaternary morphine salts such as morphine-N-oxide.
• the danger of the preparation according to the invention being improperly taken intravenously can also be further reduced by the opiate being present in retarded form.
• the preparation according to the invention contains 1 to 2000 mg, preferably 100 mg to 1500 mg of opiate.
• the quantity can be adjusted according to the needs of the patient.
• the opiate is administered in combination with at least one antagonist.
• Naloxone or one of its derivatives or salts is a preferred opiate antagonist.
• Naloxone has the following structural formula:
• the antagonist in particular the naloxone, can be administered in all the usual administration forms according to the present invention.
• Physiologically acceptable water-soluble salts such as hydrochloride or hydrochloride dihydrate are preferred.
• the antagonist is present in the preparation according to the invention in either retarded or non-retarded form. The non-retarded form is preferred.
• Naloxone acts as an opiate antagonist in completely the opposite way to opiate agonists such as morphine: naloxone blocks the opiate receptors and reduces the effect of the morphine. A correspondingly high dose of naloxone completely eliminates the effect of morphine, and there are withdrawal symptoms. This effect is known and is exploited for example to treat opiate poisoning by administering naloxone.
• naloxone has a significant antagonistic effect when it is administered intravenously, but scarcely any when administered orally.
• the reason for this is that, when administered orally, naloxone experiences a pronounced first-pass metabolism and is therefore rapidly broken down.
• the bioavailability of orally administered naloxone is very low, sometimes less than 5%, and the opioidal effect of the morphine is scarcely impaired by the naloxone.
• the naloxone would greatly impair the opioidal effect of the morphine.
• the patient is forced to take the medicinal product orally.
• the intravenous, nasal or pulmonary pathway is undoubtedly the administrative route of choice, because of the speed with which the effect (“kick”) sets in.
• the result of taking it intravenously would be merely frustration, however, as the effect of the morphine is greatly reduced by the intravenously effective naxolone, and in extreme cases even eliminated, which would lead to the immediate appearance of withdrawal symptoms.
• the antagonists which can be used within the framework of the present invention have a bioavailability of less than 5%, preferably less than 3%, particularly preferably less than 1%.
• bioavailability is meant in this case the percentage of the active ingredient which appears unchanged in the blood when the mixture according to the invention is administered orally.
• the bioavailability of an intravenously injected medicinal product is by definition 100%.
• Bioavailability is also defined in WHO Annex 9, 1996.
• the low bioavailability ensures that a drug addict does not feel a “kick” when he takes the preparation according to the invention, but a relatively low level of antagonists is maintained in the patient's blood. It is surprising in this connection that, despite the low bioavailability, a substitution therapy with the advantages listed below is made possible.
• At least one antagonist is used.
• the combination of morphine and naloxone is particularly preferred.
• retarded and non-retarded active ingredients comprise retarded morphine and non-retarded antagonists, retarded morphine and retarded antagonists, non-retarded morphine and non-retarded antagonists as well as non-retarded morphine and retarded antagonists.
• Naloxone can be the preferred antagonist in each case.
• the quantity of antagonists in the preparation is high enough to reduce the undesired side-effects caused by the morphine, for example constipation.
• the use according to the invention can contribute to a reduction or avoidance of the change in the body mass index (BMI) as well as a reduction or avoidance of the tooth decay which is to be observed in patients prescribed a substitute.
• BMI body mass index
• naloxone preferably 1 to 5 mg of naloxone are contained per tablet per 100 mg of retarded morphine.
• a particularly preferred embodiment of the present invention is a preparation with 100 mg to 1500 mg of retarded morphine in combination with 1 mg to 5 mg of naloxone.
• naloxone is preferably used as an additional active ingredient according to the present invention
• all opiate antagonists with a corresponding low bioavailability can be used when administered orally.
• Such compounds are known to a person skilled in the art.
• quantity details and method of administration what was said above concerning naloxone applies analogously to this substance.
• the preparation according to the invention is characterized in that it cannot be taken intravenously, for the above reasons.
• the preparation according to the invention can be taken orally (e.g. as a solution or tablet).
• the corresponding administration forms are known to a person skilled in the art.
• the preparation according to the invention contains the additives customary for this, which are also sufficiently known to a person skilled in the art and require no further explanation here.
• the morphine used in the following examples is a powder with a grain size ⁇ 400 ⁇ m; manufacturer: McFarland.
• the naloxone used is supplied by Sanofi-Aventis and the Eudragit by Röhm GmbH, Darmstadt, Germany.
• naloxone retard pellets and morphine retard pellets which are packed into a hard-gelatine capsule are described below:
• Naloxone HCl, Eudragit RSPO, Eudragit RLPO and stearic acid are mixed in a twin-cylinder mixer.
• the mixed material is continuously introduced into a twin-screw extruder and the resulting strands collected on a conveyor belt.
• the strands are cooled on the conveyor belt.
• the cooled strands are cut into pellets in a pelletizer.
• the pellets are screened and the desired screened portion collected.
• Stearyl alcohol flakes are passed through an impact grinding mill.
• Morphine HCl, Eudragit RSPO, ethyl cellulose and stearyl alcohol are mixed in a twin-cylinder mixer.
• the mixed material is continuously introduced into a twin-screw extruder and the resulting strands collected on a conveyor belt.
• the strands are cooled on the conveyor belt.
• the cooled strands are cut into pellets in a pelletizer.
• the pellets are screened and the desired screened portion collected.
• the pellets prepared in Examples 1A and 1 B are packed into a hard-gelatine capsule in the ratio 1:1 and the latter is sealed.
• the preparation of retard tablets which contain morphine HCl and naloxone HCl is described below, wherein both active ingredients are present as granules.
• the granules containing the morphine and the naloxone are dispersed in a matrix with controlled release.
• the granules are combined with molten wax (stearyl alcohol) in order to obtain waxed granules which are then ground, mixed with other excipients and compressed into tablets.

Applications Claiming Priority (3)

Related Parent Applications (1)

Related Child Applications (1)

Publications (1)

Family

ID=36675685

Family Applications (2)

Family Applications After (1)

Country Status (19)

Cited By (3)

Families Citing this family (5)

Citations (7)

Family Cites Families (19)

• 2006
  • 2006-01-19 EP EP06100578A patent/EP1810678A1/de not_active Withdrawn
• 2007
  • 2007-01-19 DE DE502007003589T patent/DE502007003589D1/de active Active
  • 2007-01-19 CN CNA2007800026334A patent/CN101370503A/zh active Pending
  • 2007-01-19 PL PL07704010T patent/PL1976524T5/pl unknown
  • 2007-01-19 CN CN201410124301.5A patent/CN103893179A/zh active Pending
  • 2007-01-19 EP EP07704010.3A patent/EP1976524B2/de active Active
  • 2007-01-19 CA CA2637458A patent/CA2637458C/en active Active
  • 2007-01-19 US US12/161,397 patent/US20100221339A1/en not_active Abandoned
  • 2007-01-19 UA UAA200810463A patent/UA92380C2/ru unknown
  • 2007-01-19 AU AU2007206914A patent/AU2007206914B2/en active Active
  • 2007-01-19 ES ES07704010.3T patent/ES2345286T5/es active Active
  • 2007-01-19 RS RS20100341A patent/RS51388B2/sr unknown
  • 2007-01-19 DK DK07704010.3T patent/DK1976524T4/en active
  • 2007-01-19 PT PT07704010T patent/PT1976524E/pt unknown
  • 2007-01-19 EA EA200870182A patent/EA014539B1/ru unknown
  • 2007-01-19 SI SI200730285T patent/SI1976524T1/sl unknown
  • 2007-01-19 WO PCT/EP2007/050540 patent/WO2007082935A1/de active Application Filing
  • 2007-01-19 AT AT07704010T patent/ATE465735T1/de active
• 2010
  • 2010-06-24 CY CY20101100578T patent/CY1110152T1/el unknown
  • 2010-07-05 HR HRP20100373TT patent/HRP20100373T4/hr unknown
• 2014
  • 2014-12-04 HK HK14112247.0A patent/HK1198744A1/xx unknown
• 2016
  • 2016-06-20 US US15/187,374 patent/US10507205B2/en active Active

Patent Citations (7)

Also Published As

Similar Documents

Legal Events